Skip to main content
Celltrion, Inc. logo

Celltrion, Inc. — Investor Relations & Filings

Ticker · 068270 ISIN · KR7068270008 LEI · 988400JFZG785WJX3D68 KO Manufacturing
Open in API
Filings indexed 1,282 across all filing types
Latest filing 2025-08-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 068270

About Celltrion, Inc.

https://www.celltrion.com/

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Recent filings

Filing Released Lang Actions
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Celltrion, covering the period from January 1, 2025, to June 30, 2025. It contains comprehensive financial statements, business descriptions, management analysis, and governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details the acquisition of shares by a major shareholder (Celltrion Holdings) through market purchases. This type of filing is a standard regulatory disclosure for insider/major shareholder transactions, which falls under the 'Director's Dealing' (DIRS) category in the provided schema.
2025-08-14 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure regarding payment methods, payment periods, and dispute resolution mechanisms as required by the Fair Transactions in Subcontracting Act (하도급법). It provides specific financial data for a defined period (2025.01.01 - 2025.06.30) for Celltrion. Since this is a specific regulatory disclosure filing that does not fit into the other categories like financial reports or announcements, it falls under the 'Regulatory Filings' category.
2025-08-13 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed by Celltrion. It details the specific dates, quantities, and prices of shares repurchased by the company over a defined period. This falls directly under the category of 'Transaction in Own Shares' (POS), which covers share buybacks.
2025-08-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the share transactions (purchases) made by Seo Jung-jin, a director/chairman of Celltrion. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it documents insider trading activity by a company executive.
2025-08-07 Korean
[기재정정]연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a regulatory filing from Celltrion titled '연결재무제표기준영업(잠정)실적(공정공시)' (Provisional Earnings Release based on Consolidated Financial Statements). It provides a correction (정정신고) to a previously filed earnings report, detailing updated financial figures such as revenue, operating profit, and net income for the second quarter of 2025. Since it is an initial announcement of financial results (even if it is a correction of a previous release), it falls under the Earnings Release category. Q2 2025
2025-08-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.